A Study to Investigate Fadraciclib (CYC065), in Subjects With Leukemia or Myelodysplastic Syndrome (MDS)
Status:
Recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
This is a 2-part, phase 1/2, open-label, multicenter study designed to evaluate the safety
and efficacy of fadraciclib (formerly CYC065) administered orally BID. This study consists of
Phase 1 and Phase 2 components in subjects with Leukemia or Myelodysplastic syndrome (MDS)
who have progressed despite having standard therapy or for which no standard therapy exists.